Nubeqa (darolutamide) is not a chemotherapy drug. It belongs to a completely different class of cancer treatment called androgen receptor inhibitors. While chemotherapy works by attacking rapidly dividing cells throughout the body, Nubeqa works by blocking the specific hormonal signals that prostate cancer needs to grow.
How Nubeqa Differs From Chemotherapy
Traditional chemotherapy drugs are cytotoxic, meaning they poison cells that divide quickly. This approach kills cancer cells but also damages healthy fast-growing cells like those in hair follicles, the gut lining, and bone marrow. That’s why chemo often causes hair loss, nausea, and a weakened immune system.
Nubeqa takes a targeted approach. Prostate cancer cells rely on male hormones (androgens) to fuel their growth. Nubeqa blocks the androgen receptor, which is the docking station on cancer cells where these hormones attach. Specifically, it prevents androgens from binding to the receptor, stops the receptor from moving into the cell’s nucleus, and shuts down the gene activity the receptor would normally switch on. By cutting off the hormonal fuel supply, Nubeqa slows or stops tumor growth without the widespread cell damage that chemotherapy causes.
In clinical practice, Nubeqa is classified as an androgen receptor axis-targeted therapy, or ARAT. Other drugs in this category include enzalutamide and apalutamide. These are considered a separate treatment strategy from chemotherapy, though in some cases they may be used alongside it.
What Nubeqa Is Prescribed For
The FDA has approved Nubeqa for two stages of prostate cancer. The first approval, in 2019, covered non-metastatic castration-resistant prostate cancer, meaning the cancer hasn’t spread to other parts of the body but is still growing despite hormone-lowering treatment. In this setting, the pivotal clinical trial showed that men taking Nubeqa lived a median of 40.4 months without their cancer spreading, compared to 18.4 months for those on placebo. That’s roughly double the time.
The second approval, finalized in June 2025, expanded Nubeqa’s use to metastatic castration-sensitive prostate cancer, where the cancer has spread but still responds to hormone therapy. In this more advanced setting, Nubeqa can be used either alone with standard hormone-lowering treatment or in combination with the chemotherapy drug docetaxel. That combination, Nubeqa plus chemo plus hormone therapy, showed added survival benefits compared to chemo and hormone therapy alone.
What Taking Nubeqa Looks Like
Unlike chemotherapy, which typically requires IV infusions at a clinic, Nubeqa is an oral medication you take at home. The standard dose is two 300 mg tablets, twice a day, with food. You swallow the tablets whole. If you miss a dose, you take it as soon as you remember before the next scheduled one, but you don’t double up.
This pill-based routine is a significant practical difference from chemotherapy. There are no infusion appointments, no IV lines, and no post-treatment recovery days built into a cycle. You simply take the tablets with meals as part of your daily routine.
Side Effects Compared to Chemo
Because Nubeqa doesn’t attack cells indiscriminately, its side effect profile is considerably milder than chemotherapy. You won’t experience the hair loss, severe nausea, or immune suppression that typically accompany chemo drugs like docetaxel.
One notable advantage Nubeqa has even over other drugs in its own class is limited penetration into the brain. In preclinical studies, Nubeqa crossed the blood-brain barrier at roughly one-tenth the rate of enzalutamide, a similar androgen receptor inhibitor. This matters because drugs that reach the brain more easily tend to cause more fatigue, cognitive fog, falls, and in rare cases, seizures. Nubeqa’s lower brain penetration suggests a reduced risk of these central nervous system side effects, which is a meaningful quality-of-life consideration for men who may be on the drug for years.
When Nubeqa Is Used With Chemotherapy
The fact that Nubeqa sometimes gets paired with chemo may be part of why people wonder if it’s a chemo drug itself. For metastatic castration-sensitive prostate cancer, one proven treatment approach combines Nubeqa with docetaxel (a true chemotherapy drug) and androgen deprivation therapy. In this three-drug regimen, each component works through a different mechanism: docetaxel kills dividing cells, androgen deprivation therapy lowers hormone levels body-wide, and Nubeqa blocks whatever hormonal signals still reach the cancer cells.
These are complementary but fundamentally different strategies. Nubeqa and docetaxel are no more the same type of drug than an antibiotic and a pain reliever prescribed together for an infection. They address the same disease through entirely different biological pathways.